Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements.
Net profit22.68 millionEGP · −67.0% vs the same period a year earlier
Total assets575 millionEGP · −37.0% vs the same period a year earlier
Shareholders' equity50.05 millionEGP · −89.2% vs the same period a year earlier
Operating cash flow22.04 millionEGP · +128.5% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q3 2024 was about 22.68 million EGP, down −67.0% from 68.75 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 575 million EGP, and shareholders' equity about 50.05 million EGP.
- Operating cash flow for Q3 2024 was positive at 22.04 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit22.68 million68.75 million−67.0%
Gross profit101 million189 million−46.3%
Total assets575 million913 million−37.0%
Total liabilities525 million448 million+17.1%
Shareholders' equity50.05 million465 million−89.2%
Total liabilities and equity575 million913 million−37.0%
Operating cash flow22.04 million-77.33 million+128.5%
Investing cash flow28.04 million-791 thousand+3644.8%
Financing cash flow17.04 million-9.88 million+272.5%
Net change in cash67.12 million-88 million+176.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy